Your browser doesn't support javascript.
loading
Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference.
de Jong, L A; Koops, M; Gout-Zwart, J J; Beinema, M J; Hemels, M E W; Postma, M J; Brouwers, J R B J.
Afiliación
  • de Jong LA; Unit of PharmacoTherapy, PharmcoEpidemiology and PharmcoEconomics, University of Groningen, Groningen, the Netherlands.
Neth J Med ; 76(10): 426-430, 2018 12.
Article en En | MEDLINE | ID: mdl-30569888
In 2012, the Dutch Health Council published a report addressing barriers for an early and broad introduction of direct oral anticoagulants (DOACs). The report raised concerns about the lack of an antidote, adherence, lack of monitoring in the case of overdose and the increased budget impact at DOAC introduction. In the past decade, international studies have shown that DOACs can provide healthcare benefits for a large number of patients. This has led to an increase in the prescription of DOACs, as they are an effective and user-friendly alternative to vitamin K antagonists (VKAs). Unlike VKAs, DOACs do not need monitoring of the international normalized ratio due to more predictable pharmacokinetics. However, the number of prescriptions of DOACs in the Netherlands is still lagging, compared to other European countries. This article highlights the potential health gains in the Netherlands if the use of DOACs were to increase, based on current international experience.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Accidente Cerebrovascular / Tromboembolia Venosa / Inhibidores del Factor Xa Tipo de estudio: Etiology_studies / Prognostic_studies Aspecto: Patient_preference Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Neth J Med Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Países Bajos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Accidente Cerebrovascular / Tromboembolia Venosa / Inhibidores del Factor Xa Tipo de estudio: Etiology_studies / Prognostic_studies Aspecto: Patient_preference Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Neth J Med Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Países Bajos